Cantel Medical (NYSE:CMD) reported results for the first quarter, posting double-digit revenue and earnings growth to start its fiscal year. It's hard to ask for more from the medical-supply company.

Cantel Medical results: The raw numbers


Q1 2018

Q1 2017

Year-Over-Year Change


$212.8 million

$187.7 million


Income from operations

$31.6 million

$27.1 million


Earnings per share




Data source: Cantel Medical.

What happened with Cantel Medical this quarter?

  • Sales of endoscopy products led the group with revenue growth of 19.8%. Some of that came from the addition of BHT, a German company Cantel acquired in August. But even backing out acquisitions, endoscopy sales of grew 10.7% organically. A lot of the growth is coming from the installed base of endoscopy machines driving recurring revenue, which increased 20.8% year over year.
  • Water purification and filtration sales increased 7.4%, and the unit still has a backlog of $66 million worth of products that have been ordered but need to be shipped and installed.
  • Sales of healthcare disposables increased 5.7%, but income from the segment increased at a higher rate thanks to higher-margin branded products.
  • The company generated $30.1 million in cash from operations, up 20.7% year over year, helping it pay down $19.3 million of debt. Net debt now sits at $130.8 million.
Gloved hands of a doctor using an endoscope

Image source: Getty Images.

What management had to say

Jorgen Hansen, Cantel's president and CEO, said the company isn't done making acquisitions yet and hinted they could come sooner rather than later:

From an M&A perspective, we are very encouraged with the health of our pipeline and are optimistic about potential deals in the coming quarters. We are evaluating opportunities to acquire new businesses and technologies in all of our existing segments, as well as exploring potential new verticals within infection prevention.

Hansen also highlighted some new products the company is working on to boost revenue organically:

We have new line extensions on the procedure side in endoscopy, which obviously is very important since this is a high-growth, high-profit area. We are planning to launch new [inaudible] water systems and portable water systems in our water business, and we are adding a couple of new products in health disposables or dental business, as well as in the consumables side of the business with some new technologies and great markets. So we feel really good about the pipeline and our ability to continue to drive organic growth through our commercial teams.

Looking forward

Management is sticking with guidance for its current fiscal year that was given when it reported last quarter. Revenue should grow between 12.5% and 13.5%, with earnings per share (EPS) expected to grow by 20% to 25% while adjusted EPS will should increase only 10% to 13%.

As long as Cantel can keep doing what it did in the first fiscal quarter, it should be able to hit those goals.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.